Oncology consultancy Physiomics said it had won a new contract from Japanese pharmaceutical company Astellas Pharma. Physiomics said the precise value of the contract could not be disclosed for reasons of commercial confidentiality, however it was around 20% of the company's annual income for the year through June 2019. The contract was for a modelling project involving Physiomics' Virtual Tumour immuno-oncology model and the work was expected to be completed this calendar year. At 9:04am: (LON:PYC) Physiomics PLC share price was -1.25p at 8.05p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.